Treatment Satisfaction and Quality of Life with Tirzepatide Versus Dulaglutide Among Japanese Patients with Type2 Diabetes: Exploratory Evaluation of the SURPASS J-mono Trial.

Abstract

Treatment satisfaction in diabetes management is vital to achieving long-term clinical outcomes. This analysis evaluated treatment satisfaction among patients with type2 diabetes (T2D) after 52weeks of treatment with once-weekly tirzepatide (5, 10, and 15mg) compared with dulaglutide 0.75mg. This exploratory analysis of the phase3 SURPASS J-mono trial assessed treatment satisfaction using the Japanese translation of the Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change versions (DTSQc). Subgroup analyses were posthoc and conducted for the DTSQc overall treatment satisfaction score based on age (< 65 or ≥ 65years), sex (male or female), baseline body mass index (BMI; < 25 or ≥ 25kg/m2), and baseline glycated hemoglobin (≤ 8.5% or > 8.5%). Baseline DTSQs scores were similar among patients across all treatment arms. Overall, trends showed higher satisfaction among patients who received any tirzepatide dose compared with those who received dulaglutide after 52weeks of treatment. Mean overall DTSQc treatment satisfaction scores at week52 were significantly higher with tirzepatide 5, 10, and 15mg versus dulaglutide 0.75mg (11.5, 12.1, and 12.3, respectively, vs 8.9; P < 0.001). The DTSQc perceived frequency scores for unacceptable hyperglycemia were significantly lower with tirzepatide 5, 10, and 15mg versus dulaglutide 0.75 mg (- 1.7, - 1.8, and - 2.3, respectively, vs - 0.6; P < 0.001), while scores for unacceptable hypoglycemia were similar across all treatment arms, ranging from - 0.8 to - 1.1. Subgroup analyses showed increased treatment satisfaction with tirzepatide compared with dulaglutide in the < 65years (P < 0.001) and baseline BMI ≥ 25kg/m2 subgroups (P < 0.01 or < 0.001) and similar treatment satisfaction across treatment arms in the ≥ 65years and BMI < 25 kg/m2 subgroups. Patients with T2D reported higher treatment satisfaction with once-weekly tirzepatide (5, 10, and 15mg) compared with dulaglutide 0.75mg after 52weeks of treatment. ClinicalTrials.gov, NCT03861052.